For PE groups, physician entrepreneurs, and strategic acquirers targeting the $15B+ U.S. aesthetic medicine market, the acquisition vs. de novo decision hinges on regulatory complexity, key-man risk, and time to cash flow.
Cosmetic surgery centers occupy a unique position in lower middle market healthcare: they generate 15–30% EBITDA margins, benefit from recurring non-surgical revenue, and serve a growing demographic — but they are also heavily regulated, heavily dependent on physician reputation, and highly sensitive to consumer confidence cycles. For buyers evaluating entry into this space, the core question is whether to acquire an established center with existing patient flow, licensed facilities, and trained staff, or to build a de novo practice from the ground up. The answer depends heavily on your background, capital position, timeline to returns, and appetite for regulatory and operational complexity. This analysis walks through both paths with specifics to the cosmetic surgery industry.
Find Cosmetic Surgery Center Businesses to AcquireAcquiring an existing cosmetic surgery center gives you immediate access to a licensed, accredited facility, an established patient database, trained aesthetic staff, and a revenue-generating procedure mix that may include both high-margin surgical cases and high-volume non-surgical repeat treatments like Botox and fillers. In a highly fragmented market where local surgeon reputation and patient trust are the primary competitive moats, buying an established center collapses years of brand-building into a single transaction. For buyers who can navigate CPOM compliance and physician retention risk, acquisition is typically the faster and lower-risk path to meaningful cash flow.
Private equity groups executing add-on acquisitions onto an existing aesthetic platform, strategic acquirers such as regional cosmetic surgery chains, and physician entrepreneurs with existing clinical credibility who want to step into an established center rather than build patient volume from zero.
Building a cosmetic surgery center from scratch — a de novo approach — offers complete control over location, brand positioning, procedure mix, technology, and organizational structure. There is no legacy malpractice exposure, no key-man transition risk, and no premium paid for someone else's goodwill. However, the barriers to entry in cosmetic surgery are substantial: obtaining facility accreditation, recruiting a board-certified surgeon, building a patient base in a competitive local market, and generating meaningful surgical volume typically requires 2–4 years and significant upfront capital. The de novo path is rarely the right choice for financial buyers but may suit physician founders with an existing patient following who want to build equity in their own platform.
Board-certified plastic or facial surgeons with an existing patient following who are spinning out of a hospital system or group practice, or highly capitalized physician entrepreneurs willing to accept a 3–5 year investment horizon in exchange for full equity ownership and no acquisition premium.
For the vast majority of lower middle market buyers — PE groups, strategic acquirers, and entrepreneurial investors — acquisition is the clearly superior path into the cosmetic surgery center market. The regulatory barriers to entry, the time required to build surgical volume and local brand equity, and the capital intensity of a de novo buildout make acquisition the faster, more predictable route to cash flow. The critical variable is not buy versus build — it is identifying a target with genuine transferable value: diversified procedure revenue, associate physicians who can sustain volume post-transition, clean malpractice history, and accredited facility status. For physician founders with an existing patient base and willingness to accept a 3–5 year horizon, de novo development can create superior long-term equity value — but it requires capitalization, operational discipline, and patience that most financial buyers are unwilling to commit. If you can find a center with manageable key-man risk at a 4–5x EBITDA multiple, buy it.
Does the target center have associate physicians or mid-level providers who can sustain at least 50% of current revenue if the selling surgeon departs — and if not, are you willing to accept the key-man risk at the price being asked?
Are you prepared to structure the deal as an MSO/PC asset purchase to comply with corporate practice of medicine laws in the target state, and do you have healthcare-specialized legal counsel experienced in CPOM-compliant deal structures?
Does the center hold current AAAHC or JCAHO accreditation, valid DEA registrations, and all required state facility licenses — or will you be inheriting an accreditation gap that requires 12–24 months to cure?
Can you verify the last 3 years of financial statements, identify personal expenses run through the business, and confirm that patient volume trends are stable or growing independent of a single physician's marketing activity?
If you were to build this center from scratch in the same market, what would it cost and how long would it take to reach the same revenue level — and does that de novo timeline and capital requirement justify paying the acquisition premium at the current asking multiple?
Browse Cosmetic Surgery Center Businesses For Sale
Skip the build phase — acquire existing customers, revenue, and cash flow from day one.
Cosmetic surgery centers in the $1M–$5M revenue range typically trade at 3.5–6x EBITDA. Centers at the lower end of the range often reflect key-man concentration, aging equipment, or limited associate physician depth. Centers commanding 5–6x multiples typically have diversified procedure revenue, associate physicians who drive measurable volume, AAAHC or Joint Commission accreditation, and strong non-surgical recurring revenue from Botox, fillers, and laser treatments that does not depend on the selling surgeon personally.
Yes, but the structure must comply with the corporate practice of medicine laws in the relevant state. Most states prohibit non-physician entities from directly employing physicians or owning the professional corporation that holds the medical license. The standard compliant structure uses a Management Services Organization (MSO) — owned by the non-physician investor — that provides all non-clinical business services to a physician-owned Professional Corporation (PC). The MSO earns a management fee from the PC, capturing the economic value of the business. This structure must be carefully drafted to avoid fee-splitting violations and should be reviewed by healthcare regulatory counsel in the specific state of operation.
Yes. Cosmetic surgery centers are generally eligible for SBA 7(a) loans, which can cover up to 70–80% of the acquisition price for deals up to $5M. The SBA will typically require the buyer to inject 10–20% equity and may require a seller note covering an additional 10–15%. Key underwriting factors include the practice's 3-year financial history, the buyer's creditworthiness, and evidence that the revenue is not entirely dependent on a single physician. SBA lenders with healthcare practice experience will scrutinize key-man concentration closely — centers where the selling surgeon drives 80%+ of revenue may face SBA underwriting challenges or require enhanced transition agreements.
Most deals in the cosmetic surgery space require the selling physician to remain in a transition role for 12–36 months, depending on the degree of key-man concentration and whether associate physicians are already in place. Shorter transitions of 6–12 months are feasible when the center has multiple providers and strong non-surgical revenue. Longer earnout periods of 24–36 months tied to revenue retention are common when the selling surgeon drives a significant share of surgical volume. Sellers should expect post-close compensation structured as a combination of base salary, clinical per-diem, and earnout tied to patient retention metrics.
The single greatest risk in acquiring a cosmetic surgery center is physician key-man dependency — specifically, buying a practice where 70–80% or more of revenue is attributable to the selling surgeon's personal reputation and patient relationships, only to see that revenue erode after the transition period ends. Unlike a build where you control the physician from inception, an acquisition requires you to accurately assess whether the practice has genuine transferable goodwill: associate providers, documented systems, loyal repeat non-surgical patients, and marketing infrastructure that generates new patient inquiries independent of the selling surgeon's personal brand. Buyers who skip this analysis and rely solely on historical financials often discover post-close that the revenue they paid 5x for was not transferable.
More Cosmetic Surgery Center Guides
Get access to acquisition targets with real revenue, real customers, and real cash flow.
Create your free accountNo credit card required
For Buyers
For Sellers